Migraine is a debilitating disorder of the CNS. Although therapeutic options for migraine attacks have tremendously advanced with the development of triptans more than a decade ago, several conditions (such as vascular disease) restrict their use. Moreover, some patients do not respond to triptans and other currently available medications. Therefore, treatment alternatives are needed. Study data show that 5-HT 1F receptor agonists successfully abort migraine attacks. These data also suggest a favorable vascular side-effect profile of these substances, which could be beneficial for migraine treatment in subjects with cardiac or vascular disease. We discuss the current knowledge of 5-HT 1F receptor-mediated effects, in part by comparing them to triptans, and we also summarize data from basic research and clinical trials. Key Words: 5-HT 1F , serotonin receptor, migraine, treatment, triptans.
vessels, it is unlikely that therapeutic plasma concentration can lead to myocardial ischemia in patients without coronary heart disease and normal coronary circulation. 11 However, rare cases of stroke, 12,13 myocardial infarction, 14 -16 and arrhythmia 17 have been reported in relation to triptan use. Therefore, the use of triptans is not recommended in patients with manifestation of or at certain risk for cerebrovascular or coronary artery disease. For patients with the aforementioned risk and for people older than 65 years of age, new drugs without vascular side effects, but with the same or even better potency than triptans are needed to abort migraine attacks.
Unlike the 5-HT 1B receptors, the 5-HT 1D receptors can be mainly found on neuronal tissues. Expression of both the 5-HT 1B and the 5-HT 1D receptor have been detected in the trigeminal ganglion 4, 18, 19 and expression of the 1D receptor subtype has additionally been detected on sensory trigeminal fibers. 5, 20 The suggestion has been made that triptans exert their effects by reducing neurogenic inflammation and inhibiting neurotransmitter release mainly through the stimulation of the 5-HT 1D receptor. Although neurogenic inflammation (first described in experimental animals) has never been convincingly demonstrated in man, neuropeptide release (i.e., calcitonin gene-related peptide) could be shown in migraine and cluster headaches. [21] [22] [23] The notion that selective 5-HT 1D receptor agonists do not mediate vascular effects was previously believed to offer a safe strategy for migraine treatment. However, a randomized, double blind, placebo-controlled study with a selective 5-HT 1D receptor agonist (PNU-142633) failed to show any statistically significant treatment effects. Surprisingly PNU-142633 was also associated with cardiac adverse events, such as chest pain, mild atrioventricular block and QTc prolongation. 24 The findings of this study suggest that the anti-migraine effects of triptans are mediated through a 5-HT receptor other than the 1D subtype.
In addition to serotonin 1B and 1D subtypes, several other HT 1 receptors have been cloned. Among these, the so-called 5-HT 1F receptor appears to be promising for the treatment of migraine. This hypothesis is supported by the fact that triptans also have a high affinity for the 5-HT 1F receptor in addition to the affinity at the 1B and 1D receptors. 25, 26 The 5-HT 1F receptor is a member of the 5-HT 1 receptor family of G protein coupled receptors that inhibit adenylyl cyclase, which is prominently expressed in the brain, uterus, and mesentery. 27, 28 In detail, the 5-HT 1F receptor can be found in parts of the trigeminal system, such as the trigeminal ganglion (only messenger RNA [mRNA]) 4 and the trigeminal nucleus caudalis (mRNA and protein). 29 -31 This receptor is also expressed in the neocortex and the hippocampus 30 and mRNA can be detected in human brain vessels. 4 Isolated microvessels and capillaries consistently show the expression of 5-HT 1B , 5-HT 1D , and 5-HT 1F receptor mRNA. In contrast to the 1D receptor subtype, expression of 5-HT 1F mRNA can not be found in microvascular cell cultures of endothelial or smooth muscle cells of cerebral vessels. 8 However, the mRNA of the 5-HT 1F receptor (and various other 5-HT receptors) can be detected in astrocytes, which are intimately associated to intraparenchymal blood vessels. 8, 32 Pharmacological activation of 5-HT 1F receptors through selective agonists does not lead to vasoconstriction of cerebral arteries. 26, 33 Moreover, no vasoconstrictive activity of 5-HT 1F receptor agonists could be observed in peripheral arteries. 25, 34, 35 In conclusion, the 5-HT 1F receptor is very unlikely to be involved in the regulation of the vascular tone in the human brain. Therefore, novel selective serotonin 1F receptor subtype agonists without or with only minimal affinity to 5-HT 1B or 5-HT 1D receptors could be promising for anti-migraine therapy.
5-HT 1B , 5-HT 1D , and 5-HT 1F receptors share some interesting properties, as they have been found to be co-localized with glutamate in trigeminal ganglia neurons in the rat. 36 Glutamate is a major excitatory neurotransmitter in the CNS, and is supposed to be involved in the mechanisms of cortical spreading depression, the hypothesized pathophysiological correlate of the migraine aura. 37 Furthermore, glutamate is believed to contribute to the activation of the trigeminovascular system and central sensitization. 38 Most recently, it has been described that effective prophylactic treatment of migraine reduces elevated plasma glutamate levels in these patients. 39 The co-localization of the 5-HT 1B , 5-HT 1D , and 5-HT 1F receptors and glutamate could indicate a possible inhibition of glutamate release by 5-HT 1F receptor agonists and/or triptans, which could provide an additional explanation for their anti-nociceptive effects.
A general analgesic action of 5-HT 1F receptor agonists is unclear. In one study, the 5-HT 1F receptor agonist LY334370 did not abort hyperalgesia in rats and also failed to modify spinal nociceptive reflexes in the rabbit. 40 However, newer, contradicting data show an antinociceptive effect of the 5-HT 1F receptor agonist LY344864 in the rat formalin test (quantification of nociceptive behavior after injection of formalin into the hind paw). 41 More data are needed to answer this question.
Several selective 5-HT 1F receptor agonists have been developed in the past. Among these are LY334370, 42 
LY344864
, 43 and LY349950. 44 The latest synthesized 5-HT 1F receptor agonist that has been proposed to be effective in migraine is COL-144. 45 Some of these substances have been tested in experimental migraine models.
5-HT 1F RECEPTOR AGONISTS IN MIGRAINE

5-HT 1F RECEPTOR AGONISTS INHIBIT NEUROGENIC INFLAMMATION
An experimental animal model that has been widely used to study efficacies of acute anti-migraine therapies is the so called "neurogenic inflammation" model. In this model neurotransmitter release from trigeminal fibers is measured indirectly by quantifying plasma protein extravasation in the dura mater after electrical stimulation of the trigeminal ganglion. 46 Intravenous administration of several 5-HT receptor agonists led to an attenuation of dural plasma protein extravasation. The strongest effects were expressed by the 5-HT 1F receptor agonist LY334370, followed in a rank order by naratriptan Ͼ LY302148 Ͼ LY306528 ϭ zolmitriptan Ͼ dihydroergotamine Ͼ sumatriptan Ͼ rizatriptan Ͼ L-694,247. Interestingly, the potency of the 5-HT 1 agonists in this model was correlated to their affinity to the 5-HT 1F receptor, whereas no correlation could be found between potency and affinity to the 5-HT 1B and 5-HT 1D receptors. The authors concluded that inhibition of plasma protein extravasation is primarily mediated through the 5-HT 1F receptor, explaining a possible anti-migraine effect of the 5-HT 1F receptor agonists. 25 In a similar study design, the administration of the 5-HT 1F receptor agonist LY344684 intravenously 10 minutes or orally 75 minutes before trigeminal stimulation also led to a dose-dependent reduction of plasma protein extravasation in the dura mater. 43 It is noteworthy to mention that antagonists of the neurokinin-1 receptor and agonists of the 5-HT 1D receptor block neurogenic inflammation, but they do not abort migraine attacks. 24, 47 Lately, Peroutka postulated that the ability of drugs to selectively inhibit neuronal plasma extravasation in rodents has no predictive value for the efficacy in the acute treatment of migraine. 48 Activity of the 5-HT 1F receptor can also be measured by assessing the binding of the stable analogue [35S] GTP␥S. This assay can be used to analyze neuronal 5-HT 1F receptor coupling in substantia nigra, and LY334370 was the most potent compound compared to the other tested compounds, such as sumatriptan, naratriptan, zolmitriptan, methysergide, and dihydroergotamine. Furthermore, there was a statistically significant correlation between the 5-HT 1F receptor agonist potency in [35S]GTP␥S binding and the degree of inhibition of trigeminal nerve-stimulated dural plasma protein extravasation. 49 
5-HT 1F RECEPTOR AGONISTS DECREASE STIMULUS INDUCED C-FOS IN THE TRIGEMINAL NUCLEUS CAUDALIS
One experimental model uses chemical, mechanical, or electrical activation of C-and A␦ fibers of the trigeminal nerve to induce the expression of the immediate early gene c-fos within cells of the trigeminal nucleus caudalis. 50 Sumatriptan has been shown to decrease c-fos-like immunoreactivity in the trigeminal nucleus caudalis after noxious meningeal stimulation, indicating inhibition of the activity of neurons. 51 Both sumatriptan and the 5-HT 1F receptor agonist LY344864 (intraperitoneally) also decrease intracisternally administered capsaicin induced c-fos-like immunoreactivity within laminae I and laminae II of the trigeminal nucleus caudalis in mice. Sumatriptan was approximately 15-fold more potent than LY344864. Blocking experiments revealed that sumatriptan attenuates c-fos-like immunoreactivity via 5-HT 1B receptors, whereas LY344864 acts via 5-HT 1F receptors. 52 As LY344864 is able to cross the bloodbrain barrier, 43 this substance is likely to inhibit the response via central 5-HT 1F receptors on trigeminal nucleus caudalis neurons. Sumatriptan has no strong ability to cross the intact blood brain barrier, 53 and there is also no clear evidence that the blood brain barrier disrupts during a migraine attack. 54 Therefore, it was proposed that sumatriptan predominantly acts on peripheral 5-HT 1B receptors (e.g., terminals of the trigeminovascular neurons). However, several animal studies demonstrated a CNS effect of sumatriptan. These findings imply that sumatriptan exerts antinociceptive activity also within the CNS, 55 in addition to its peripheral trigeminovascular effects.
In another study, the oral pretreatment of rats with the 5-HT 1F receptor agonists LY334370 and LY397584 significantly decreased the number of second order neurons in the trigeminal nucleus caudalis, which stained positive for induced c-fos protein. The blocking potency of both compounds (minimal effective dose of LY334370 1 g/kg and of LY397584 1 mg/kg) was clearly different, which was attributed to differences of their ability to penetrate the blood brain barrier. 56 The latter could influence the properties of 5-HT 1F receptor agonists to inhibit c-fos expression in the trigeminal nucleus caudalis. 57 In summary, the finding that stimulation of the 5-HT 1F receptor was able to modulate the activity of the trigeminal system identifies this receptor as a possible target for anti-migraine drugs. Based on these findings, the efficacy of 5-HT 1F receptor agonists to abort migraine could be dependent on their ability to cross the blood brain barrier.
5-HT 1F RECEPTOR AGONISTS AND VASCULAR PROPERTIES
The development of triptans was based on the vascular theory of migraine (i.e., the vasodilatation of brain vessels activates trigeminovascular nerve endings and leads to the generation of pain). Accordingly, triptan-mediated vasoconstriction would then lead to migraine pain relief.
Different animal models exist to investigate vascular properties of drugs. The vasoconstrictive effects of sumatriptan were first demonstrated in the isolated saphenous vein of the dog, which is a tissue that shows contractile responses to anti-migraine agents similar to the human middle cerebral artery. 58 Other studies also identified the saphenous vein of the rabbit as a tissue with contractile response to serotonin receptor agonists similar to both the human cerebral arteries and also to the coronary arteries. 59 5-HT 1B , 5-HT 1F , and, to a smaller extent, 5-HT 1D receptor mRNAs have been identified in human cerebral arteries. 4 The 5-HT 1B receptor mRNA has also been found in human coronary arteries 7 and in peripheral blood vessels. 60, 61 The 5-HT 1F mRNA receptor could only be detected in a very low amount in human coronary arteries. 33 The mRNA of all three receptors has been detected in the saphenous vein of the rabbit. 61, 62 Although sumatriptan, zolmitriptan, rizatriptan, and naratriptan contracted the saphenous vein of the rabbit, no contraction could be achieved with high doses of the 5-HT 1F receptor agonist LY344864. A significant correlation between the contractile potency and the affinities at the 5-HT 1B and 5-HT 1D receptors, but not the 5-HT 1F receptor could be demonstrated for these ligands. 35 Another 5-HT 1F receptor agonist (i.e., LY334370) failed to produce a contractile response in the rabbit's saphenous vein in doses as great as 10 Ϫ4 M in a similar study.
Modest precontraction with PGE 2␣ augmented the contractile response to sumatriptan and ergotamine. Some vasoconstriction could be archived with LY344864 after precontraction with PGE 2␣ but only when doses exceeded 10 Ϫ5 M (i.e., concentrations that probably also activated 5-HT 1B receptors). 63 Application of LY334370 in concentrations up to 10 Ϫ5 M to human cerebral vessels had no significant vasoconstrictor effect. 40 These findings are supported by another study in the human middle meningeal artery using agonists with different affinities to the 5-HT 1B , 5-HT 1D , and 5-HT 1F receptor, and several 5-HT 1B and 5-HT 1D receptor antagonists. A significant correlation between vasoconstrictor potency in human middle meningeal artery and binding affinity to the 5-HT 1B receptors was observed. In contrast, a weak, but not statistically significant relationship between vasoconstrictor potency and binding affinity at 5-HT 1D receptors, and no relationship between vasoconstrictor potency and 5-HT 1F receptor affinity, could be found in these vessels. Most importantly, these results led to the conclusion that vasoconstriction in the middle meningeal artery is 5-HT 1B receptor-mediated without any contribution from 5-HT 1F receptors. 26 In summary, several studies demonstrate the existence of 5-HT 1F receptors on cerebral and also peripheral blood vessels. However, activation of the 5-HT 1F receptor does not lead to vasoconstriction. Therefore, vasoconstriction can not be a mechanism that accounts for the antimigraine effect of these compounds.
5-HT 1F RECEPTOR AGONISTS IN THE TREATMENT OF MIGRAINE ATTACKS-CLINICAL TRIALS
A number of 5-HT 1F receptor agonists have been developed, but the first published substance to enter a clinical trial was LY334370, a substance with a 100-fold higher selectivity for the 5-HT 1F receptor than the 5-HT 1B and 5-HT 1D receptors. 25 Phase I studies were presented in 1998 and showed good tolerability in a dose Յ 400 mg with central side effects similar to these of triptans (weakness, somnolence, and dizziness). Cardiovascular side effects were not reported. Adverse events were mostly mild to moderate in severity and did not last longer than 24 hours. 64 A phase II study was later conducted with 99 migraine patients who had moderate or severe migraine headaches in a randomized, placebo controlled, double blind, parallel design of three single oral doses (20, 60 , or 200 mg) of LY334370 and placebo. In the 200 and 60 mg treatment groups, the following outcomes after 2 h were significantly better than in the placebo group: headache response, pain freedom, sustained response, and sustained pain-free rates. The primary endpoint was the sustained response after 2 h, which is defined as a reduction in migraine headache from moderate to severe to mild or none. The primary endpoint was achieved in 31% for 60 mg LY334370, 52% for 200 mg, and 8% in the placebo group. The pain-free rate at 2 h was 23% in the 60 mg group and 34% in the 200 mg group (placebo, 4%). These rates are slightly higher than in most of the triptan studies. However, an active triptan comparator was not included in the study. Headache recurrence rate was low, which was attributed to the long half-life of LY334370 (14 -16 h). The most frequent adverse events (i.e., asthenia, dizziness, somnolence, and paresthesia) were observed much more often after treatment with LY334370 than commonly seen with triptans ( Table 1 ). The relatively high effective doses in this trial were still lower than the drug concentrations that are needed to constrict the human cerebral or coronary arteries. Based on the experimental and clinical data, the authors of the study concluded that LY334370 mediates its anti-migraine action not through peripheral vascular effects, but through central mechanisms (i.e., blockade of transmission of nociceptive impulse within trigeminal nucleus caudalis). 65 Unfortunately, clinical trials of LY334370 were halted in 1999 for toxicity in animals and no further development for the compound is in sight.
Because of these promising clinical data, a series of new 5-HT 1F receptor agonists were developed that finally led to the synthesis of COL-144 (CoLucid Pharmaceuticals Inc. [Research Triangle Park, NC]; formerly LY573144). This substance, which has recently been given the name Lasmiditan, is an agonist with greater selectivity and improved bioavability compared with
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LY334370. COL-144 has a high affinity to the 5-HT 1F receptor (binding Ki ϭ 2.21 Ϯ 0.22) with a very low affinity to other 5-HT 1 receptors (5-HT 1B : Ki ϭ 1043 Ϯ 124; 5-HT 1D : Ki ϭ 1357 Ϯ 156). Unlike triptans, COL-144, which is not considered to be a triptan, has functional selectivity for 5-HT 1F receptors which is Ͼ450-fold higher than for 5-HT 1B and 5-HT 1D receptors ( Table  2 ). The substance does not cause constriction of the saphenous vein of the rabbit in concentrations up to 10 Ϫ4 M. COL-144 also inhibits stimulus-induced c-fos expression in the trigeminal nucleus caudalis of the rat and reduces dural plasma protein extravasation in a standard experimental setup in experimental animals 1 h after oral dosing. 45 The efficacy and an improved tolerability of COL-144 in migraine headaches was demonstrated in a first placebo-controlled study. The study involved 130 patients who were not on prophylaxis and who had moderate to severe migraine headaches. These patients received doses from 2.5 to 45 mg of COL-144 or a placebo as an intravenous infusion for 20 minutes. The headache response of the patients was superior in the 10, 20, 30, and 45 mg dose groups compared to the placebo (54.2 to 75% vs 45.2%) with a statistically significant linear doseresponse rate. COL-144 was generally well tolerated with a similar adverse event profile as LY334370 (i.e., paresthesia, dizziness, and heaviness). Cardiac side effects were not observed. 66 The oral compound of COL-144 was studied afterward in a phase I trial in healthy males, in dosing ranges from 2.5 to 400 mg. All doses were well tolerated with no clinically significant effects on vital signs, orthostatic responses, safety laboratories, or electrocardiograms. The most common adverse events at doses of 100 mg and greater were drowsiness, dizziness, and paresthesia. Doses of 50 mg and greater achieved plasma levels previously associated with efficacy of the intravenous administration route with a slight delay in Tmax. 67 Data from both studies have only been presented in abstract form so far. Just recently, a double blind, placebo-controlled phase II study with the oral formulation of COL-144 in doses ranging from 50 to 400 mg in the acute treatment of migraine attacks was performed, but the results have not yet been evaluated. So far, this is the most promising 5-HT 1F receptor agonist in clinical trials.
CONCLUSION
Experimental and clinical data show that activation of the 5-HT 1F receptor is efficacious in animal models of migraine, and more importantly in the acute treatment of migraine attacks. Cerebral vasodilatation might be one element in the generation of migraine pain. The lack of 5-HT 1F agonists to constrict cerebral vessels, but to alleviate migraine attacks, supports the hypothesis that vasoconstriction is not fundamentally necessary to terminate migraine attacks. Moreover, the efficacy of 5-HT 1F agonists also supports the hypothesis that central mechanisms (such as the transmission of nociceptive signals within the trigeminal system, which can be attenuated by the activation of the 5-HT 1F receptor) are key elements in the pathophysiology of migraine.
Oral 5-HT 1F receptor agonists are a promising class of drugs for the acute treatment of migraine attacks. They appear to have a safety advantage in comparison with the 
